Agenus (@Agenus

Agenus

1,509 posts

Agenus

@Agenus_Bio

Our mission is to harness the power of the immune system to bring therapies with curative intent to individuals living with cancer. bit.ly/4eXrlgY

Massachusetts, USA

Joined July 2013

Agenus
@Agenus_Bio
Jan 22, 2024
Agenus joined oncology leaders at @ASCO #GI24. We are proud to partner with @pashtoonkasi who presented data from neoadjuvant BOT/BAL in colorectal cancer. The findings underscore the potential to help #patients in earlier stages of #CRC. Learn more: bit.ly/48Lke82
7.2K
Agenus
@Agenus_Bio
Jun 17, 2021
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer The FDA has set a target action date of December 16, 2021. investor.agenusbio.com/news-releases/…
Agenus
@Agenus_Bio
Apr 27, 2020
$AGEN IN ACTION: Scientists protect front-line healthcare workers #Edith Nourse Rogers Memorial Veterans Hospital. 3D printed masks can be sanitized - learn more! agenusbio.com/covid-masks/ @MassDVS @DeptVetAffairs www0.bostonglobe.com/news/nation/20…
Agenus
@Agenus_Bio
Jun 28, 2024
New data from the NEST clinical trial was presented at @myESMO's #ESMOGI24 - results demonstrated significant tumor reductions in MSS #coloncancer patients treated with botensilimab/balstilimab in the #neoadjuvant setting. Learn more: bit.ly/3W2dSgn
00:00
8.2K
Agenus
@Agenus_Bio
Feb 25, 2019
THE WORLD's FIRST electronic security token in #healthcare, BEST, is NOT a #cryptocurrency; It is a novel mechanism designed by us to provide product specific financing. Learn how BEST is intended to help expand our AGEN2034 (anti-PD1) program bit.ly/2SsB8QK #oncology
Agenus
@Agenus_Bio
Feb 25, 2019
Our latest Newsletter focuses on our Biotech Electronic Security Token (BEST)! Learn about: What is BEST? What are its benefits? How it affects our shareholders? ..and More. Read here: agenusbio.com/wp-content/upl… #innovation #biotech #blockchain #oncology #Immunotherapy #healthcare
Agenus
@Agenus_Bio
May 16, 2024
Today we announced that Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA to discuss our botensilimab/balstilimab therapy for relapsed or refractory metastatic colorectal cancer. Learn more: bit.ly/3yqGtCY
1.7K
Agenus
@Agenus_Bio
Oct 22, 2023
Agenus is proud to unveil the latest research from our investigational #botensilimab programs, showcasing significant advancements across our colorectal, pancreatic, lung, melanoma, and sarcoma studies. #ESMO2023 A live webcast will be hosted at 1 pm EDT: investor.agenusbio.com/news/news-deta…
3.8K
Agenus
@Agenus_Bio
Dec 20, 2018
$AGEN announced partnership with Gilead to develop #Immunotherapy for patients with cancer. investor.agenusbio.com/2018-12-20-Gil…
Agenus
@Agenus_Bio
Mar 27, 2023
We’re proud to announce positive data showing a 33% overall response rate for our novel multifunctional #CTLA4 #botensilimab in combination with #balstilimab in recurrent platinum refractory/resistant #OvarianCancer. Learn more: investor.agenusbio.com/news-releases/…
1.1K
Agenus
@Agenus_Bio
Jun 26, 2018
Driven by innovation & speed and powered by the right combination of science & people—see how we're pursuing our passion and advancing toward our goal to cure cancer. This is our story: vimeo.com/273094053 #immunotherapy @big3bioBOS $AGEN
Agenus
@Agenus_Bio
Aug 26, 2021
Balstilimab Monotherapy Data Published in Gynecologic Oncology Objective response rate of 20% and median duration of response not reached with 14.6 month median follow-up in PD-L1+ tumors Responses seen across all histology subgroups investor.agenusbio.com/news-releases/…
Agenus
@Agenus_Bio
Jan 22, 2025
#BreakingNews: Today, we announced new data highlighting BOT/BAL across multiple lines of treatment in #ColorectalCancer. Find the details of our five #ASCOGI presentations here: bit.ly/3WoDjsb #GI25
1.6K
Agenus
@Agenus_Bio
Sep 16, 2021
$AGEN combination of balstilimab plus zalifrelimab doubles responses in 2L cervical cancer in data to be presented at ESMO investor.agenusbio.com/index.php/news…
Agenus
@Agenus_Bio
Jul 2, 2024
As shown last week at #ESMOGI24, our botensilimab/balstilimab investigational therapy offered new hope for this MSS-#colorectalcancer patient, achieving a complete response in seven weeks. See the full presentation here: bit.ly/4cquLqL #Immunotherapy #CancerResearch
1.4K